Efficacy and Safety of an Essential Oil-Based Product System for Immune Support

Overview

This randomized, double-blind, placebo-controlled clinical trial will evaluate the safety and efficacy of an essential oil-based product system for immune support in healthy adolescents and adults aged 18-45 years. Participants will be randomized to receive aromatic, topical, internal, or combined use of the investigational product or matching placebo for 30 days. The aromatic intervention consists of overnight diffusion, the topical intervention consists of diluted application to specified areas prior to bedtime, and the internal intervention consists of oral capsule administration twice daily. Study visits will occur at baseline and at the end of the 30-day intervention period. Primary outcomes include changes in immune-related biomarkers, including complete blood count, comprehensive metabolic panel, salivary immunoglobulin A (IgA), and inflammatory cytokines (IL-6, TNF-α, IL-10). Epigenetic markers will also be evaluated. Secondary outcomes include validated subjective assessments of immune status and overall well-being, as well as evaluation of safety and tolerability. The study includes an adaptive design with interim analysis to assess enrollment and study continuation parameters.

This study is a randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the safety and efficacy of a multi-modal essential oil-based product system in healthy adolescents and adults aged 18-45 years. Approximately 20 participants per arm will be enrolled and randomized, with the option for sample size expansion following a planned interim analysis. Participants will be randomized to receive either the investigational product or matching placebo administered through one of four intervention approaches: aromatic use, topical use, internal use, or combined use of all three modalities. The intervention period will be 30 days. The aromatic intervention consists of diffusion of the assigned product overnight (approximately 8 hours) using a standardized protocol. The topical intervention consists of application of a diluted preparation to specified skin areas prior to bedtime. The internal intervention consists of oral capsule administration twice daily with meals. Participants assigned to the combined group will use all three modalities concurrently. Placebo preparations will be matched for appearance and administration method. Study assessments will occur at baseline and at the end of the 30-day intervention period. Biological samples will be collected for evaluation of immune-related biomarkers, including complete blood count (CBC), comprehensive metabolic panel (CMP), salivary immunoglobulin A (IgA), and inflammatory cytokines (interleukin-6 \[IL-6\], tumor necrosis factor alpha \[TNF-α\], and interleukin-10 \[IL-10\]). Epigenetic analyses will also be conducted to evaluate changes in gene expression patterns associated with immune function. Validated subjective outcome measures, including the PROMIS Global Health instrument and the Immune Status Questionnaire, will be administered to assess perceived immune status and overall well-being. Participants will complete compliance and tolerability reporting throughout the study period. Safety monitoring will include assessment of adverse events, with particular attention to dermatologic, respiratory, and gastrointestinal symptoms potentially associated with essential oil exposure. The study incorporates an adaptive design with planned interim analysis after initial enrollment targets are reached to guide potential expansion or completion of study arms. The primary objective is to evaluate changes in immune-related biomarkers following 30 days of product use. Secondary objectives include assessment of subjective immune status, hedonic response, and safety/tolerability of aromatic, topical, internal, and combined administration modalities.